Home > Publications database > Synthesis and application of a thiol-reactive HBED-type chelator for development of easy-to-produce Ga-radiopharmaceutical kits and imaging probes. > print

001     167329
005     20240909140820.0
024 7 _ |a 10.1039/D0OB02513E
|2 doi
024 7 _ |a pmid:33527964
|2 pmid
024 7 _ |a 1477-0520
|2 ISSN
024 7 _ |a 1477-0539
|2 ISSN
037 _ _ |a DKFZ-2021-00277
041 _ _ |a eng
082 _ _ |a 540
100 1 _ |a Klika, Karel
|0 P:(DE-He78)c53db83479d3d1265967405af71f69bb
|b 0
|e First author
|u dkfz
245 _ _ |a Synthesis and application of a thiol-reactive HBED-type chelator for development of easy-to-produce Ga-radiopharmaceutical kits and imaging probes.
260 _ _ |a Cambridge
|c 2021
|b Royal Society of Chemistry
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1725883665_24152
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:A390#LA:E030# /Division of Radiopharmaceutical Chemistry,2021 Mar 4;19(8):1722-1726
520 _ _ |a In radiopharmaceutical syntheses, maleimide is commonly used for linking thiol-bearing bioactive molecules to metal-complexing ligands (chelators). However, due to instability of the resulting linkage, phenyloxadiazolyl methylsulfone (PODS) was developed as an alternative to maleimide. This coupling strategy has never been attempted with HBED which is a powerful chelator for gallium-radiolabeling especially at ambient temperature. Here we present HBED-CC-PODS as a bifunctional chelator scaffold for the site-selective conjugation of thiol-bearing vectors and [68Ga]Ga-radiolabeling.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Da Pieve, Chiara
|b 1
700 1 _ |a Kopka, Klaus
|b 2
700 1 _ |a Smith, Graham
|b 3
700 1 _ |a Makarem, Ata
|0 P:(DE-He78)e5df498f08a8708fc5b826f0eca1db41
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1039/D0OB02513E
|g p. 10.1039.D0OB02513E
|0 PERI:(DE-600)2097583-1
|n 8
|p 1722-1726
|t Organic & biomolecular chemistry
|v 19
|y 2021
|x 1477-0539
909 C O |p VDB
|o oai:inrepo02.dkfz.de:167329
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)c53db83479d3d1265967405af71f69bb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)e5df498f08a8708fc5b826f0eca1db41
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Signalling pathways, cell and tumor biology
|x 0
914 1 _ |y 2021
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
|d 2020-08-21
|w ger
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2020-08-21
|w ger
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2020-08-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1200
|2 StatID
|b Chemical Reactions
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1210
|2 StatID
|b Index Chemicus
|d 2020-08-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-08-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ORG BIOMOL CHEM : 2018
|d 2020-08-21
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-08-21
920 2 _ |0 I:(DE-He78)E030-20160331
|k E030
|l Radiopharmazeutische Chemie
|x 0
920 1 _ |0 I:(DE-He78)A390-20160331
|k A390
|l AG Wirkstoffforschung
|x 0
920 1 _ |0 I:(DE-He78)E030-20160331
|k E030
|l Radiopharmazeutische Chemie
|x 1
920 0 _ |0 I:(DE-He78)A390-20160331
|k A390
|l AG Wirkstoffforschung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A390-20160331
980 _ _ |a I:(DE-He78)E030-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21